Director dealing

RNS Number : 1218S

Physiomics PLC

06 July 2020

 

6 July 2020

Physiomics plc

("Physiomics") or (the "Company")

Director dealing

Physiomics reports that Dr Jim Millen, CEO, has transferred 85,715 ordinary shares of 0.4p each in the capital of the Company ("Ordinary Shares"), acquired during the recently placing, announced on 27 May 2020, to his account with The Share Centre for nil consideration, effective 2 July 2020.  The beneficial ownership of the Ordinary Shares remains unchanged and accordingly, Dr Millen remains interested in 530,356 Ordinary Shares representing approximately 0.55% of the Company's issued share capital.

PDMR/PCA FCA Transaction Notification

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Dr Jim Millen
2.	Reason for the Notification
a)	Position/status	Chief Executive Officer
b)	Initial notification/amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Physiomics plc
b)	LEI	213800A71DSZ6ABMTQ91
4.	Details of the transaction(s):section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv)each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Ordinary shares of 0.4p each in the share capital of the Physiomics plc
	Identification code	ISIN: GB00BDR6W943
b)	Nature of the Transaction	Transfer to broking account
c)	Price(s) and volume(s)	Price(s) Volume(s) N/A 85,715
d)	Aggregated information Aggregated volume Price	N/A - single issuance
e)	Date of the transaction	2 July 2020
f)	Place of the transaction	London Stock Exchange, AIM Market (XLON)

Enquiries:

Physiomics plc

Dr Jim Millen, CEO

[phone]

Strand Hanson Ltd (NOMAD)

Richard Tulloch & James Dance

[phone]

Hybridan LLP (broker)

Claire Louise Noyce

[phone]

Notes to Editor

About Physiomics

Physiomics plc (AIM: PYC ) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company's Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 70 projects, involving over 30 targets and 60 drugs, and has worked with clients such as Merck KGaA, Merck & Co, Bayer and Lilly.

Based in Oxford UK, the Company works with clients worldwide to support their pre-clinical and clinical oncology development programs. Its team of scientists and computer modelling experts provide bespoke solutions encompassing data, analytics and insight.

Physiomics senior management has academic and commercial expertise, including over 120 years collectively of working in oncology and/or computational biology and over 120 publications in peer reviewed journals that have attracted thousands of citations.

 

END

 

 

DSHRFMPTMTTMMBM